Study shows Wegovy by Novo Nordisk reduces cardiovascular risk

Clinical Trials

Novo Nordisk has shared results from the SELECT cardiovascular outcomes trial, which show that a once-weekly subcutaneous dose of Wegovy (semaglutide 2.4mg) reduced the risk of major adverse cardiovascular events (MACE) by 20% in overweight or obese adults over the age of 45 with established cardiovascular disease (CVD) and no prior history of diabetes.

The double-blind trial enrolled 17,604 adult patients and compared the drug to a placebo dose, showing a statistically significant and superior reduction in MACE of 20% for those treated with Wegovy compared to the placebo.

Throughout the trial, the drug appeared to be safe and well-tolerated, consistent with previous trials.

Martin Holst Lange, executive vice president for Development at Novo Nordisk, commented: "People living with obesity have an increased risk of CVD but to date, there are no approved weight management medications proven to deliver effective weight management while also reducing the risk of heart attack, stroke or cardiovascular death. Therefore, we are very excited about the results from SELECT showing that semaglutide 2.4mg reduces the risk of cardiovascular events. SELECT is a landmark trial and has demonstrated that semaglutide 2.4mg has the potential to change how obesity is regarded and treated.”

The company expects to file for regulatory approvals of Wegovy for this indication expansion in the US and EU before the end of 2023, with detailed results from this trial to be presented later this year.

GSK’s RSV vaccine approved by MHRA

GSK has announced that the MHRA has authorised its Arexvy respiratory syncytial virus (RSV) vaccine for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults over the age of 60.

RNAi treatment for hypertension developed by Alnylam and Roche

Alnylam Pharmaceuticals has announced that it has entered a strategic agreement with Roche for the development and commercialisation of zilebesiran, Alnylam’s investigational RNAi therapeutic for the treatment of hypertension in patients with high cardiovascular risk.

GSK’s novel gonorrhoea vaccine gains Fast Track designation from FDA

GSK has announced that the FDA has granted fast track designation for its investigational vaccine for gonorrhoea, which is currently in an ongoing phase 2 trial assessing the efficacy of the vaccine in healthy adults aged 18 to 50 who are considered at risk of contracting gonorrhoea.

Data from Eli Lilly’s two phase 3 tirzepatide studies shared

Eli Lilly has announced results from its two phase 3 tirzepatide studies in adult patients with obesity or who are overweight with weight-related comorbidities, excluding type 2 diabetes.

First official long COVID-19 treatment could emerge from the NIH’s RECOVER initiative

As of 31 July 2023, the NIH launched the first trials of its ‘researching COVID to enhance recovery’ (RECOVER) initiative.

GSK’s RSV vaccine approved by MHRA

RNAi treatment for hypertension developed by Alnylam and Roche

GSK’s novel gonorrhoea vaccine gains Fast Track designation from FDA

Data from Eli Lilly’s two phase 3 tirzepatide studies shared

First official long COVID-19 treatment could emerge from the NIH’s RECOVER initiative

Pharmafocus

Categories

Social Footprints